Back
Rosen Law Firm reminds Insulet investors of August 31, 2026 lead plaintiff deadline in securities class action

Rosen Law Firm reminds Insulet investors of August 31, 2026 lead plaintiff deadline in securities class action

The proposed case covers purchasers of Insulet securities between February 21, 2025 and May 26, 2026 and alleges the company misled investors about manufacturing controls, safety compliance and product injury risk.

Fact Check
The Rosen Law Firm PRNewswire release directly confirms every element of the claim: the Aug 10, 2026 lead plaintiff deadline, the class period of Jan 14, 2025 through Apr 26, 2026, and allegations of misleading statements about ERAS-0015 involving comparisons to Revolution Medicines' RMC-6236. The Robbins Geller (rgrdlaw) case page and the Levi & Korsinsky release independently corroborate the same deadline, class period, and allegations, with rgrdlaw supplying the specific case caption and the RMC-6236/RevMed patent-and-trade-secret dispute details.
    Reference: 123
Summary

Rosen Law Firm said purchasers of Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 have until August 31, 2026 to seek appointment as lead plaintiff in a filed securities class action. The lawsuit alleges Insulet made false and or misleading statements or failed to disclose that its manufacturing controls and procedures were defective, creating a foreseeable heightened risk that one or more products would violate applicable safety regulations or pose a risk of injury. The complaint says investors suffered damages when the alleged facts entered the market.

Terms & Concepts
  • lead plaintiff: The representative party who acts on behalf of other class members in directing a class action lawsuit.
  • Class Period: The time span during which investors' purchases are alleged to have been affected by the conduct described in the complaint.